Global Longitudinal Strain in Cardio-Oncology: A Review.
Grzegorz LaskawskiMaja HawryszkoAleksandra Liżewska-SpringerIzabela Nabiałek-TrojanowskaEwa LewickaPublished in: Cancers (2023)
Several therapies used in cancer treatment are potentially cardiotoxic and may cause left ventricular (LV) dysfunction and heart failure. For decades, echocardiography has been the main modality for cardiac assessment in cancer patients, and the parameter examined in the context of cardiotoxicity was the left ventricular ejection fraction (LVEF). The assessment of the global longitudinal strain (GLS) using speckle tracking echocardiography (STE) is an emerging method for detecting and quantifying subtle disturbances in the global long-axis LV systolic function. In the latest ESC guidelines on cardio-oncology, GLS is an important element in diagnosing the cardiotoxicity of oncological therapy. A relative decrease in GLS of >15% during cancer treatment is the recommended cut-off point for suspecting subclinical cardiac dysfunction. An early diagnosis of asymptomatic cardiotoxicity allows the initiation of a cardioprotective treatment and reduces the risk of interruptions or changes in the oncological treatment in the event of LVEF deterioration, which may affect survival.
Keyphrases
- left ventricular
- heart failure
- aortic stenosis
- cardiac resynchronization therapy
- hypertrophic cardiomyopathy
- ejection fraction
- acute myocardial infarction
- left atrial
- mitral valve
- palliative care
- oxidative stress
- rectal cancer
- computed tomography
- prostate cancer
- robot assisted
- stem cells
- pulmonary hypertension
- blood pressure
- percutaneous coronary intervention
- clinical practice
- bone marrow
- acute heart failure
- replacement therapy
- free survival